| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.12 | 0.003 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | 0.098 | 0.006 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.13 | 0.006 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.006 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | -0.082 | 0.007 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.008 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.17 | 0.008 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.009 |
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | -0.098 | 0.01 |